Browsing by Author "Nag, Sagorika"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Publication Advances in the Molecular Etiology of Severe Combined Immunodeficiency and Its Screening(Turkish Society of Immunology, 2023) Mahapatra, Ananya; Verma, Henu Kumar; Nag, Sagorika; Singh, Santosh; Khattri, Arun; Bhaskar, L.V.K.S.Severe combined immunodeficiency (SCID) is the most severe heterogeneous group of inherited disorders characterized by profound abnormalities such as humoral and cell-mediated immunity defects and hindered natural killer cell development and function. The knowledge of the molecular basis of SCID is essential for precise diagnosis and early treatment. In recent years, new genetic defects that cause SCID have been discovered, and the molecular and immunological mechanisms of SCID have been better understood. SCID symptoms include candidiasis, chronic diarrhea, failure to grow, and oral thrush. Hematopoietic stem cell transplantation, enzyme replacement therapy, and gene therapy are used to treat SCID. The prevalence of SCID varies worldwide. More than 80% of SCID infants have no family history of the condition. However, the development of a newborn screening test has enabled SCID detection before symptoms appear, ensuring that affected infants receive life-saving treatments. Countries that organize newborn screening programs for SCID can detect patients in their early stages of life and treat them accordingly. This review will serve as a source of up-to-date information on the identification of various genetic disorders that cause SCID, as well as their clinical characteristics, treatments, and diagnosis options, potentially saving the lives of many infants before pathogenic infections occur. � 2023 by the Turkish Society of Immunology.Publication Sialyltransferases and Neuraminidases: Potential Targets for Cancer Treatment(Multidisciplinary Digital Publishing Institute (MDPI), 2022) Nag, Sagorika; Mandal, Abhimanyu; Joshi, Aryaman; Jain, Neeraj; Srivastava, Ravi Shanker; Singh, Sanjay; Khattri, ArunCancers are the leading cause of death, causing around 10 million deaths annually by 2020. The most common cancers are those affecting the breast, lungs, colon, and rectum. However, it has been noted that cancer metastasis is more lethal than just cancer incidence and accounts for more than 90% of cancer deaths. Thus, early detection and prevention of cancer metastasis have the capability to save millions of lives. Finding novel biomarkers and targets for screening, determination of prognosis, targeted therapies, etc., are ways of doing so. In this review, we propose various sialyltransferases and neuraminidases as potential therapeutic targets for the treatment of the most common cancers, along with a few rare ones, on the basis of existing experimental and in silico data. This compilation of available cancer studies aiming at sialyltransferases and neuraminidases will serve as a guide for scientists and researchers working on possible targets for various cancers and will also provide data about the existing drugs which inhibit the action of these enzymes. � 2022 by the authors.